Disease-Modifying Drugs for Multiple Sclerosis Must Be Globally Available According to Therapeutic Guidelines Suitable to Different Regions of the World
AuthID
P-002-4WW
P-002-4WW
© 2024 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service